Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

In February, the National Institutes of Health (NIH) announced a cut of “indirect expenses” in its funding for research ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting new research aimed at understanding how study ...

Mats Sundgren, PhD, senior industry science director, European Institute for Innovation through Health Data (i-HD), discusses how the integration of artificial intelligence, real-world data, and ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

Final overall survival results from the Phase III APHINITY trial show a 17% reduction in the risk of death at 10 years for ...

In this video interview, Krinx Kong, chief commercial officer, Cognivia, discusses how clinical operations professionals ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...